| Name | Title | Contact Details |
|---|
BCY LifeSciences Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Andau Medical is a Canadian Medical Device and Dental Device company focused on providing the market with quality technologies that improve patient outcomes and enhance the clinical experience in delivering exceptional patient care.
Trimel Pharmaceuticals Corporation is a Canadian specialty pharmaceutical company focused on bringing innovative products to market that improve the patient experience and produce strong investor returns. The Corporation holds a licence for the development and marketing rights to certain products utilizing a bioadhesive intranasal gel drug delivery technology platform and owns a novel unit-dose dry powder inhaler/nasal dispersion system (“TriVair™”). The Corporation is focussing its present efforts on the development and application of these technologies for therapeutic categories such as (a) male hypogonadism (“low testosterone” or “Low-T”) and (b) female orgasmic disorder. Additionally, the Corporation owns the Canadian rights to ESTRACE® and is overseeing its distribution and marketing in Canada. The Corporation’s present drug delivery technology platforms are intended to create products that are expected to be innovative, safer, possibly more effective, easier to use and more practical than competitive products on the market.
Aridis is a privately held biotechnology company located in San Jose, CA, USA which is focused on infectious diseases. Aridis has a strong portfolio of anti-infective product candidates, a human monoclonal antibody discovery platform technology, and best-in-class formulation technologies available for partnering. Our product portfolio comprises two monoclonal antibodies currently at Phase 2 clinical testing in patients, and two additional anti-infective drug candidates entering the IND development stage. Aridis’ suite of anti-infective monoclonal antibodies offers opportunities to profoundly impact current approaches to infection control. Aridis has raised over $20m in grant funding from leading institutions such as the National Institutes of Health, US Dept. of Defense, US Dept. of Health and Human Services’ BARDA, USAID, PATH/Gates Foundations, and Regional Centers of Excellence.
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe`s leading biopharmaceutical companies, with a strong scientific core. Located in Switzerland – a biotech hub of Europe – Idorsia is specialized in the discovery and development of small molecules, to provide innovative therapeutic options.